Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells

Cancer Immunol Immunother. 2023 May;72(5):1139-1151. doi: 10.1007/s00262-022-03319-w. Epub 2022 Nov 7.

Abstract

Although T cells can develop into an exhausted state in the tumour microenvironment, tumour infiltrating T cells (TILs) are important to control tumour growth. By analysing single cell RNA-sequencing data from human tumours, we found that the transcription factors Early Growth Response 2 (EGR2) and 3 were highly induced in TILs, but not peripheral CD8 + T cells, in multiple patient cohorts. We found that deficiency of Egr2 and 3 in T cells resulted in enhanced tumour growth and fewer TILs in mouse models. Egr2 is highly expressed together with checkpoint molecules in a proportion of CD8 + TILs and Egr2high cells exhibit better survival and proliferation than Egr2-/-Egr3-/- and Egr2low TILs. Anti-PD-1 treatment increases Egr2 expression in CD8 + TILs and reduces tumour growth, while anti-PD-1 efficacy is abrogated in the absence of Egr2 and 3. Thus, Egr2 and 3 are important for maintaining anti-tumour responses of exhausted CD8 + TILs.

Keywords: Anti-PD-1; Egr2; Egr3; Tumour infiltrating lymphocytes.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / metabolism
  • Early Growth Response Protein 2 / genetics
  • Early Growth Response Protein 2 / metabolism
  • Humans
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Mice
  • Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • EGR2 protein, human
  • Early Growth Response Protein 2
  • Egr2 protein, mouse